High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2011

Study Completion Date

July 31, 2025

Conditions
Head and Neck Cancer
Interventions
BIOLOGICAL

recombinant thyroid-stimulating hormone

Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.

RADIATION

Radiodine ablation without rhTSH

Patients in this group do not receive rhTSH pre ablation.

Trial Locations (25)

BN2 5BE

Sussex Cancer Centre at Royal Sussex County Hospital, Brighton

CB2 2QQ

Addenbrooke's Hospital, Cambridge

CT1 3NG

Kent and Canterbury Hospital, Canterbury

HU16 5JQ

Castle Hill Hospital, Cottingham

DE1 2QY

Derbyshire Royal Infirmary, Derby

EX2 5DW

Royal Devon and Exeter Hospital, Exeter

GL1 3NN

Gloucestershire Royal Hospital, Gloucester

GU2 7XX

St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford

IP4 5PD

Ipswich Hospital, Ipswich

LS9 7TF

Leeds Cancer Centre at St. James's University Hospital, Leeds

LE1 5WW

Leicester Royal Infirmary, Leicester

SE1 9RT

Guy's Hospital, London

SW3 6JJ

Royal Marsden - London, London

ME16 9QQ

Maidstone Hospital, Maidstone

M20 4BX

Christie Hospital, Manchester

TS4 3BW

James Cook University Hospital, Middlesbrough

NE4 6BE

Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne

NN1 5BD

Northampton General Hospital, Northampton

HA6 2RN

Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood

NR4 7UY

Norfolk and Norwich University Hospital, Norwich

BH15 2JB

Dorset Cancer Centre, Poole Dorset

S10 2SJ

Cancer Research Centre at Weston Park Hospital, Sheffield

ST4 7LN

University Hospital of North Staffordshire, Stoke-on-Trent

CF14 2TL

Velindre Cancer Center at Velindre Hospital, Cardiff

LL 18 5UJ

Glan Clwyd Hospital, Rhyl

All Listed Sponsors
lead

University College, London

OTHER